Thursday, 11 April 2024

what are base quality scores?



When we talk about sequencing DNA, our machines are pretty clever—they don't just read the sequences; they also tell us how confident they are about what they've read. Imagine the machine encounters an A nucleotide and assigns it a quality score of Q20. According to the Phred scale, that translates to a 99% confidence level in its accuracy. While that may sound reassuring, it also means there's a 1% chance of error.

Now, consider the scale at which we're working. In a typical 30x genome project, we might analyze around 90 billion base calls. With a 1% error rate, that's potentially 900 million inaccuracies. Each base call receives its own quality score, which is determined by a complex algorithm that might as well be considered a trade secret by the manufacturers.

This scoring system is crucial for us to understand the reliability of our data. It's a bit like the machine saying, "I'm pretty sure, but let's double-check," which in the grand scheme of things, is invaluable for ensuring the accuracy of our genetic analyses.



A Phred quality score is a measure of the quality of the identification of the nucleobases generated by automated DNA sequencing.[1][2] It was originally developed for the computer program Phred to help in the automation of DNA sequencing in the Human Genome Project. Phred quality scores are assigned to each nucleotide base call in automated sequencer traces.[1][2] The FASTQ format encodes phred scores as ASCII characters alongside the read sequences. Phred quality scores have become widely accepted to characterize the quality of DNA sequences and can be used to compare the efficacy of different sequencing methods. Perhaps the most important use of Phred quality scores is the automatic determination of accurate, quality-based consensus sequences.




Thursday, 3 August 2023

An Unexpected Journey: A Reflection on Leadership, Teamwork, and Growth in a Clinical Environment


Introduction:

Working as a bioinformatician in an NHS Genomics clinical laboratory has been a multifaceted experience, filled with learning, challenges, teamwork, and patient-centered care. The dynamics of the role took an unexpected turn when I was placed in charge of the bioinformatics departament, a shift that led to incredible opportunities, responsibility (and also stress), collaboration, and personal growth.

Team Dynamics and Patient-Centered Care:

1. Learning and Collaboration: Working alongside fellow bioinformaticians, a principal bioinformatician, clinical scientists, and technicians has been a rich learning experience. The shared goal of patient care has fostered a culture of collaboration. For instance, one of the vital lessons has been the importance of communication between professionals of different backgrounds. Understanding priorities, and perspectives of varied disciplines is crucial to aligning our efforts and ensuring effective collaboration. This has required active listening, clear expression of ideas, and the willingness to learn from others. Secondly, understanding the specific needs of the laboratory, especially in the context of patient care, has been instrumental in shaping the way I approach and prioritize analyses. Recognizing that behind every data point there's a human life has guided me to always place patient needs at the forefront of our work. It’s a fine balance of scientific rigor and empathetic understanding, ensuring that our technical decisions align with clinical urgencies.

I've come to appreciate that familiarity with the unique dynamics of a clinical laboratory environment requires time and significant hands-on experience. It's not merely about mastering the technical aspects but about growing into the nuanced roles that a bioinformatician must play within a healthcare setting. Understanding the workflow, the collaboration points, the ethical considerations, and the emotional weight of our work is something that comes with continuous engagement and reflection.

This multifaceted collaboration has not only enriched my professional skills but also deepened my appreciation for the interconnectedness of our roles. It's a holistic learning journey that intertwines technical expertise, human empathy, organizational acumen, and continuous growth, all centered around the profound responsibility of patient care.


2. Patient-Centered Focus: In the field of healthcare, placing patients at the heart of everything we do is not just an ethical imperative but a guiding principle that shapes the quality, relevance, and impact of our work. In bioinformatics, this patient-centered focus is manifested in several ways:

  • Data Protection: Patients entrust us with their most personal and sensitive information: their genetic makeup. The responsibility to protect this data is paramount. Ensuring robust security measures, strict adherence to privacy laws, and transparent handling practices is not merely a legal obligation but a commitment to the dignity and autonomy of the individuals we serve. Breaches in data protection not only erode trust but can lead to significant harm such as discrimination or stigma.
  • Tailoring Analysis to Patient Needs: Bioinformaticians must align their analyses and methodologies with the specific needs of the patients. This means selecting or designing programs, algorithms, and processes that will provide the most relevant and actionable insights for clinicians. It's not about what's most convenient or cutting-edge; it's about what will yield the best outcomes for the individual patient. Whether it's identifying a rare genetic disorder or determining the optimal treatment path for a cancer patient, the precision and relevance of our work can have life-altering implications.
  • Ensuring Accuracy through Validation and Verification: The stakes are incredibly high in clinical bioinformatics. A false positive or a missed variant can lead to misdiagnosis, inappropriate treatment, or missed opportunities for intervention. Therefore, the validation (ensuring that the method measures what it is intended to measure) and verification (confirming that the method is performed correctly) of our analyses are non-negotiable. This meticulous attention to accuracy is not just a technical standard but a profound respect for the gravity of our work's impact on real lives.
  • Collaboration with Clinical Teams: Our work does not exist in isolation but is intertwined with the broader healthcare team's efforts. Understanding the clinical context, collaborating closely with medical professionals, and translating our findings into actionable insights requires empathy, communication, and a deep appreciation for the patient's journey. It's not just about data; it's about human stories, fears, hopes, and the collective pursuit of well-being.

In conclusion, the patient-centered focus in bioinformatics transcends technology and science. It's a holistic approach that acknowledges the humanity behind the data, the real-world implications of our analyses, and the ethical duty to act with integrity, compassion, and excellence. It's about recognizing that our work is not an abstract exercise in computation but a vital part of a larger mission to heal, empower, and honor the dignity of those we serve. It's what elevates our profession from a technical discipline to a noble calling within the sacred trust of healthcare.


Unexpected Leadership Opportunity:

 My supervisor left his position, leaving me with enormous responsibility. This unexpected opportunity was both thrilling and difficult, opening doors to learning while also bringing stress. This allowed me to engage with numerous real-case scenarios, enriching my understanding of the field and sharpening my analytical abilities. Though stressful at times, this role taught me resilience and adaptability, equipping me with invaluable managerial skills. The addition of colleague bioinformaticians has allowed for a more collaborative environment. Sharing analyses, seeking feedback, and problem-solving collectively has added depth and joy to the work.


Reflection on Future Aspirations and Responsibilities:

1. The Commitment to Continuous Learning: As a senior bioinformatician, the evolving landscape of genomics and bioinformatics presents both challenges and opportunities. Keeping abreast of the latest advancements, tools, and methodologies is not just a matter of professional development; it's a commitment to the patients and the community you serve. It reflects an understanding that knowledge is not static, and that excellence requires an ongoing curiosity, adaptability, and the courage to explore new horizons. It's about recognizing that the quest for improvement is a journey, not a destination.

2. Working Within the Scope of Practice: With seniority comes greater responsibility and autonomy. However, it also requires a clear and conscious understanding of one's scope of practice. This means not only recognizing my expertise and leveraging it to the fullest but also acknowledging the limits of my competence. It's about fostering collaboration, seeking guidance when needed, and making decisions that prioritize patient welfare over personal pride or ambition. It's a delicate balance that requires humility, integrity, and a steadfast dedication to the principles of ethical healthcare.

3. The Opportunity to Pursue the HSST Program: The chance to participate in the Higher Specialist Scientist Training program is more than just a career advancement opportunity. It represents a profound alignment of my personal and professional growth with the broader mission of the NHS. The HSST program is designed to cultivate leaders who are not just skilled in their field but also visionary in their approach to healthcare. It's an invitation to deepen my expertise, broaden my impact, and contribute to shaping the future of clinical genomics in a meaningful way. My lab has offered me this opportunity and I'm still wondering if I should take it this year or next year. But what I am clear about is that this is the next step to take.

4. The Interplay of Skills, Ethics, and Ambitions: My role in the clinical genomics NHS laboratory is not defined solely by my technical prowess but by a constellation of skills, values, and goals. It's about nurturing a culture of excellence, compassion, collaboration, and innovation. It's about mentoring the next generation of bioinformaticians, fostering a patient-centered ethos, and being a steward of a tradition that marries science with humanity.

Conclusion:

My professional future as a senior bioinformatician is not just a personal career trajectory; it's a vital part of a larger ecosystem of healthcare, education, research, and social responsibility. It's a path laden with challenges, opportunities, lessons, and legacies. The commitment to continuous learning, the wisdom to work within my scope of practice, and the pursuit of the HSST program are not just milestones in my journey; they are reflections of who I am and what I aspire to be. They are a testament to my dedication to my craft, my patients, my colleagues, and my own unceasing quest for growth and excellence. It's a future that is as promising as it is demanding and one that beckons with the assurance that the best is yet to come.

Monday, 10 January 2022

Bioinformatic check needed

It became more frequent that one of the data analysis required in this facility is to check that variants called by applications in a VCF file are correct by analysing BAM files. In this example, I was required to find out if a particular variant was cis or trans.

This is the email conversation:

The analysis is carried out by using Integrative Genomics Viewer (IGV).


Hi Esther,

 

Ben and I have looked at the couple of variants you want to know if they are trans or cis. They are in trans.

 

 



 

chr10:90,697,940

<hr>Total count: 254

A      : 0

C      : 130  (51%,     64+,   66- )

G      : 0

T      : 124  (49%,     64+,   60- )

N      : 0

---------------

 

chr10:90,697,948

<hr>Total count: 256

A      : 1  (0%,     1+,   0- )

C      : 126  (49%,     63+,   63- )

G      : 0

T      : 129  (50%,     61+,   68- )

N      : 0

---------------

 

 

 

From: SANDERS, Ben (SALISBURY NHS FOUNDATION TRUST)
Sent: 10 January 2022 10:24
To: DOMINGUEZ BECERRA, Manuel (SALISBURY NHS FOUNDATION TRUST)
Subject: FW: Bio-informatic check needed

 

 


 

Hi Ben

 

I submitted a request to Jira (16.12.21) but haven’t heard anything back.  Could you have a quick look  at a sample to see if two variants are in cis or trans for me.

 

‘Can we check if the two ACTA2 variants (c.868G>A p.Asp290Asn & c.860G>A p.Cys287Tyr) in WXXXXXXX  are in cis or trans (NGS_WRGL3_351).’

 

Thanks

 

Esta

 


 

Sent on December 16, 2021 1:43:24 PM GMT

Monday, 13 September 2021

Programming. What I have learnt in the last months


**Programming in Genomics Facility:**


Programming is essential in a genomics facility for analyzing vast amounts of data, filtering variants related to specific genetic conditions, and more. Building programs requires proficiency in programming languages and adherence to best practices.


**Recent Focus: Identifying Matching VCF Files:**

In the last few weeks, I have been developing a program to detect when two VCF files belong to the same patient. Key learning includes:


**A) General Programming Principles:**

   - Write for people, not just computers.

   - Maintain consistency, let the computer repeat tasks, use version control, etc.

   - Re-use and modularize code; plan for mistakes and optimize after correctness.

   - Document purpose and design; collaborate using code reviews, pair programming, and issue tracking tools.


**B) Adherence to International Standards:**

   - Complying with rules like PEP 8 and the Python style guide.

   - Tools like pylint assist in identifying errors or deviations from these standards.


**Importance for Clinical Bioinformaticians:**

   - Ensuring proper documentation and commenting is crucial.

   - Commenting makes maintenance easier, aids in bug detection, and provides essential guidance for other users.

   - Well-documented code is as vital as correctly working code, enhancing the usability and understanding of programs.


In conclusion, programming in the context of genomics demands a blend of technical expertise, adherence to international standards, and clear communication through proper documentation. These principles foster more effective collaboration and facilitate the continued development and maintenance of vital tools within the field.

Sunday, 23 May 2021

The c.288+74_359delinsTAATGA case.

This discussion revolves around a real case that was presented to me by my supervisor as part of my ongoing training. The focus of the case was on a deletion detected in a sample, specifically in exons 3 and 4 of the NF1 gene, as identified by Multiplex Ligation-dependent Probe Amplification (MLPA).


**My First Task:** To determine the exact nature of the deletion. The challenge was to confirm whether the deletion involved the entire exons 3 and 4 or if it was a smaller, more localized deletion that just happened to encompass the region where the MLPA probe was located.


The importance of making this distinction lies in understanding the precise nature of the genetic alteration, which can have profound implications for diagnosis and potential treatment. This real-world scenario provided an invaluable learning experience, highlighting the intricacies of genetic analysis and the attention to detail required in the field.




The images provided in this case study illustrate what appears to be a potential partial exon deletion, rather than a complete deletion of the entire exon.


**Investigation Details:** With guidance from my supervisor, further examination revealed that the deletion extended into the intron region between exons 3 and 4.


- **First Screenshot:** This image displays a deletion close to the sequence region immediately following exon 3.

- **Second Screenshot:** This image highlights the region of exon 4.


These findings offer a more nuanced understanding of the deletion, emphasizing the complexity of genetic variations. Such insights may have implications for the diagnosis or management of conditions associated with these gene regions. The collaborative investigation process also served as an educational opportunity, allowing me to gain hands-on experience in genetic analysis.








After this finding, I wanted to see exactly the kind of variant so I looked at base-pair resolution. Apart from the huge region deleted, a short region of 6 nucleotides was also found as shown in the next picture.





Some code I used during this search in case I need to go to the raw data quickly 

module load igv/2.3.88

igv 210205_M01875_0660_000000000-JFPJK_rpt_369891814.bam



Friday, 23 April 2021

Personal notes about NGS.


In this post, I aim to provide a concise reference guide related to various high-throughput sequencing technologies. I felt compelled to create this guide, as I've often had to refer back to these details and occasionally found it challenging to locate the specific data.

**Sanger Sequencing:**

- **Throughput:** Capable of running up to 384 samples in a single session.
- **Base Reads:** Offers read lengths of approximately 700 base pairs.
- **Daily Output:** Can produce up to 1 million bases per day.
- **Coverage:** Typically provides a 7x coverage of the sequence.

I hope that by compiling this information, I'm helping others who may encounter similar difficulties. Whether you're a seasoned expert or new to the field of high-throughput sequencing, having this information at your fingertips can be a valuable time-saver.

Illumina sequencer: 









Comparison of high-throughput sequencing methods
MethodRead lengthAccuracy (single read not consensus)Reads per runTime per runCost per 1 billion bases (in US$)AdvantagesDisadvantages
Single-molecule real-time sequencing (Pacific Biosciences)
Long-Read
30,000 bp (N50);

maximum read length >100,000 bases[79][80][81]

87% raw-read accuracy[82]4,000,000 per Sequel 2 SMRT cell, 100–200 gigabases[79][83][84]30 minutes to 20 hours[79][85]$7.2-$43.3Fast. Detects 4mC, 5mC, 6mA.[86]Moderate throughput. Equipment can be very expensive.
Ion semiconductor (Ion Torrent sequencing)up to 600 bp[87]99.6%[88]up to 80 million2 hours$66.8-$950Less expensive equipment. Fast.Homopolymer errors.
Pyrosequencing (454)700 bp99.9%1 million24 hours$10,000Long read size. Fast.Runs are expensive. Homopolymer errors.
Sequencing by synthesis (Illumina)MiniSeq, NextSeq: 75–300 bp;

MiSeq: 50–600 bp;

HiSeq 2500: 50–500 bp;

HiSeq 3/4000: 50–300 bp;

HiSeq X: 300 bp

99.9% (Phred30)MiniSeq/MiSeq: 1–25 Million;

NextSeq: 130-00 Million;

HiSeq 2500: 300 million – 2 billion;

HiSeq 3/4000 2.5 billion;

HiSeq X: 3 billion

1 to 11 days, depending upon sequencer and specified read length[89]$5 to $150Potential for high sequence yield, depending upon sequencer model and desired application.Equipment can be very expensive. Requires high concentrations of DNA.
Combinatorial probe anchor synthesis (cPAS- BGI/MGI)BGISEQ-50: 35-50bp;

MGISEQ 200: 50-200bp;

BGISEQ-500, MGISEQ-2000: 50-300bp[90]

99.9% (Phred30)BGISEQ-50: 160M;

MGISEQ 200: 300M;

BGISEQ-500: 1300M per flow cell;

MGISEQ-2000: 375M FCS flow cell, 1500M FCL flow cell per flow cell.

1 to 9 days depending on instrument, read length and number of flow cells run at a time.$5– $120
Sequencing by ligation (SOLiD sequencing)50+35 or 50+50 bp99.9%1.2 to 1.4 billion1 to 2 weeks$60–130Low cost per base.Slower than other methods. Has issues sequencing palindromic sequences.[91]
Nanopore Sequencing
Long-Read
Dependent on library preparation, not the device, so user chooses read length (up to 2,272,580 bp reported[92]).~92–97% single readdependent on read length selected by userdata streamed in real time. Choose 1 min to 48 hrs$7–100Longest individual reads. Accessible user community. Portable (Palm sized).Lower throughput than other machines, Single read accuracy in 90s.
GenapSys SequencingAround 150 bp single-end99.9% (Phred30)1 to 16 millionAround 24 hours$667Low-cost of instrument ($10,000)
Chain termination (Sanger sequencing)400 to 900 bp99.9%N/A20 minutes to 3 hours$2,400,000Useful for many applications.More expensive and impractical for larger sequencing projects. This method also requires the time-consuming step of plasmid cloning or PCR.

Sunday, 11 April 2021

What is more important - the individual privacy right or the wellbeing for society?

During my attendance at the National Information Governance training module, I found myself contemplating how data protection regulations in the UK specifically apply to genetic data. My curiosity was piqued by the potential challenges that UK rules governing the use of such data might pose to legitimate healthcare and research applications. This concern is grounded in the understanding that the sharing of genomic data can profoundly enhance medical research and healthcare delivery. The benefits of genomic data sharing are immense, especially when it comes to clinical geneticists comparing uncertain genetic results with existing databases. This comparative approach can often lead to more precise diagnoses, improved disease management, and consequently, enhanced healthcare services. To continually reap these benefits, it's essential to augment the size and diversity of genomics databases. I must admit that I'm not an expert in this area, but my preliminary reading leads me to conclude that there exists a legal gray zone. Striking the right balance between individual rights and the societal imperative of sharing genetic information seems to be a nuanced challenge. It appears that there's a lack of definitive guidance, with different laboratories interpreting the law in subtly distinct ways. The multifaceted nature of this issue allows for various approaches. Central to the debate is the question of whether we can truly identify a person through genetic data. Personal identifiable data is a double-edged sword: it possesses immense intrinsic value but can also be employed maliciously to discriminate or stigmatize individuals. A critical task is defining what constitutes identifiable versus de-identified data, as the current law makes distinctions based on these categories. For instance, if genetic data is deemed neither confidential nor identifiable, the law may permit more liberal sharing. Regrettably, these challenges are not solely technical in nature. The understanding of this complex issue extends into the realms of politics and philosophy. We must grapple with a profound question: What takes precedence, individual privacy rights or societal wellbeing? The stance taken on this question will have significant ramifications for the future of clinical genetics and my professional development. Furthermore, it's vital to recognize the political dimension to this discourse. Advocates for enhanced data sharing may perceive existing protections, such as anonymization coupled with managed access, as more robust than those primarily concerned with safeguarding individual privacy rights. The stakes in this debate are elevated, as the implications for healthcare and society are far-reaching, contingent upon the vision that is ultimately embraced.